Disclaimer

This Web site has been created solely for the purpose of providing information about services available from Richmond Pharmacology (RP). The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.

Due to web security any ideas and or information sent to RP via this Web site will be deemed not to be confidential and by sending information, you are granting RP unrestricted and irrevocable licence to use, reproduce, display, perform, modify, transmit and distribute. However RP will not release your name or otherwise publicise the fact that information was sent unless RP obtains your permission to do so or if RP is required to do so by law.

Please note that RP does not endorse any other Web sites accessed via this site or accepts any responsibility for the content or accuracy of information contained on that site. In no event will RP be liable to any party for any damages arising from any use of or access to this Web site.

Latest news

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Patient with rare bleeding disorder becomes first to test new treatment

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event